



# **Objective study validity diagnostics: a framework requiring pre-specified, empirical verification to increase trust in the reliability of real-world evidence**

Mitchell M Conover, Patrick B Ryan, Yong Chen,  
Marc A Suchard, George Hripcsak, Martijn J Schuemie

*Journal of the American Medical Informatics Association*, Volume 32, Issue 3,  
March 2025, Pages 518–525 <https://doi.org/10.1093/jamia/ocae317>



# Conflicts of Interest

- Mitch Conover, Patrick Ryan, and Martijn Schuemie are employees and shareholders of Johnson & Johnson
- Marc Suchard receives grants and contracts from US Food & Drug Administration and Johnson & Johnson



# Framework for objective diagnostics

How to assess the reliability of RWE studies?

- Diagnostics (e.g. covariate balance: standardized difference of means  $< 0.1$ )

Building on LEGEND framework: objective diagnostic measures should be used to evaluate/report validity of observational findings by either:

1. interpreting objective diagnostic results before unblinding study results
2. only unblinding results from analyses for which all objective diagnostics pass *pre-specified* thresholds

Diagnostic failures should be reported alongside unblinded results




# Study objective

- Six diagnostic metrics for comparative cohort studies:
  1. Covariate balance: maximum standardized difference of means (SDM)
  2. Empirical equipoise
  3. Expected absolute systematic error (EASE)
  4. Generalizability standardized difference of means
  5. Minimum detectable relative risk (MDRR)
- We provide conceptual overviews of each, the key assumption it tests, considerations or references when pre-specifying diagnostic thresholds



# Covariate balance: maximum standardized difference of means (SDM)

Threat to validity	Metric calculation	Threshold guidance
Confounding bias <sup>26-28</sup>	<p>The SDM compares the proportion or mean of exposed and unexposed, scaled to the pooled standardized deviation. The maximum SDM is the largest SDM measured across all observed baseline variables.</p> $SDM = \frac{(\bar{x}_T - \bar{x}_C)}{\sqrt{\frac{s_T^2 + s_C^2}{2}}}$ for continuous variables $SDM = \frac{(\hat{p}_T - \hat{p}_C)}{\sqrt{\frac{\hat{p}_T(1-\hat{p}_T) + \hat{p}_C(1-\hat{p}_C)}{2}}}$ for dichotomous variables T=target, C=comparator	<p><math>SDM_{\max} &gt; 0.10</math> conventionally interpreted to indicate the presence of confounding bias based on Austin et al. heuristic.<sup>26-29</sup></p>





# Re-using LEGEND-HTN Negative Control Experiments

- On-treatment comparisons of the effect of various monotherapy antihypertensive treatments
- Six administrative claims databases and three electronic health record databases
- Large-scale propensity score (LSPS) adjustment (stratification and variable-ratio matching) was used to control confounding
- Empirical calibration used to account for residual systematic error
  - 11,716 negative control exposure-comparator-outcome triplets





# Re-using LEGEND-HTN Negative Control Experiments

- For each negative control analysis, we implemented various diagnostic thresholds:
  - Covariate balance SDM  $< 0.10$
  - Empirical equipoise  $\geq 0.50$
  - Systematic error (EASE)  $\leq 0.25$
  - Generalizability SDM  $\leq 0.25$
  - MDRR  $\leq 10$
- We computed the distribution of diagnostics across 11,716 LEGEND-HTN negative control studies



# Covariate balance SDM < 0.1







# LEGEND Negative Control Results For Selected Diagnostics

Diagnostic threshold(s)	N (% satisfied)	EASE	EASE <sub>Δ</sub>
None	11,716 (100.0%)	0.38	-
Covariate balance SDM < 0.1	4,923 (42.0%)	0.28	-0.10
Equipoise > 0.5	2,792 (23.8%)	0.02	-0.36
Equipoise > 0.1	10,010 (85.4%)	0.33	-0.05
All*	1,633 (13.9%)	0.00	-0.38

Some diagnostics dramatically reduce systematic error but only by excluding a large share of (potentially valid) studies

\* MDRR ≤ 10, equipoise ≥ 0.50, covariate balance SDM < 0.10, generalizability SDM ≤ 0.25, systematic error (EASE) ≤ 0.25



## Key take-aways

- Objective diagnostics are crucial for evaluating and communicating the reliability of evidence generated by observational studies
- More work is needed to identify new diagnostics, establish their use across study designs (e.g. SCCS), and provide guidance for diagnostic thresholds




# BACKUP SLIDES



# Empirical equipoise

Threat to validity	Metric calculation	Threshold guidance
Confounding <sup>24</sup> Non-positivity <sup>23</sup>	$\ln\left(\frac{F}{1-F}\right) = \ln\left(\frac{S}{1-S}\right) - \ln\left(\frac{P}{1-P}\right)$ <p>F=Preference score S=Propensity score P=Fraction of people receiving target</p>	0.3 ≤ F ≤ 0.7 in more than half of patients <sup>24</sup>



Objective Diagnostic	Threat to validity	Metric calculation	Threshold guidance
<b>Minimum detectable relative risk</b>	Misinterpreting wide effect estimates from grossly underpowered studies	Compute the minimum detectable relative risk (MDRR) metric and expected standard error (SE) for a given study population, using the actual observed sample size and number of outcomes (after analytic approaches have been applied). <sup>17</sup> $mdrr = e^{\sqrt{\frac{(Z_{\beta} + Z_{1-\frac{\alpha}{2}})^2}{totalEvents * P_A * P_B}}}$	We propose MDRR < 10, although there is debate whether power calculations have utility in studies using pre-existing observational data. <sup>18-21</sup>
<b>Empirical equipoise</b>	Confounding <sup>24</sup> Non-positivity <sup>23</sup>	$\ln\left(\frac{F}{1-F}\right) = \ln\left(\frac{S}{1-S}\right) - \ln\left(\frac{P}{1-P}\right)$ <p>F=preference score S=Propensity score for receiving target P=Fraction of people receiving target</p>	0.3 ≤ F ≤ 0.7 in more than half of patients <sup>24</sup>
<b>Covariate balance maximum standardized difference of means (SDM)</b>	Confounding bias <sup>26-28</sup>	The SDM compares the proportion or mean of exposed and unexposed, scaled to the pooled standardized deviation. The maximum SDM is the largest SDM measured across all observed baseline variables. $SDM = \frac{(\bar{x}_T - \bar{x}_C)}{\sqrt{\frac{s_T^2 + s_C^2}{2}}}$ for continuous variables $SDM = \frac{(\hat{p}_T - \hat{p}_C)}{\sqrt{\frac{\hat{p}_T(1-\hat{p}_T) + \hat{p}_C(1-\hat{p}_C)}{2}}}$ for dichotomous variables           T=target, C=comparator	SDM <sub>max</sub> > 0.10 conventionally interpreted to indicate the presence of confounding bias based on Austin et al. heuristic. <sup>26-29</sup>
<b>Generalizability maximum SDM</b>	Selection bias <sup>31</sup>	Same calculation as covariate balance SDM, comparing analytic vs. target population	SDM <sub>max</sub> < 0.25 suggested as a rule of thumb to indicate that the population is “like a random sample” <sup>31,32</sup>
<b>Expected Absolute Systematic Error (EASE)</b>	Systematic error (selection, confounding, misclassification bias) <sup>1</sup>	$EASE = average( \ln(HR_{estimate}) - \ln(HR_{truth}) )$ across negative control outcome studies	A current rule of thumb is EASE < 0.25.

# Full Results Table

	LEGEND studies	LEGEND negative control studies				
Diagnostic threshold(s)	N (% satisfied)	N (% satisfied)	log-HR <sub>μ</sub> (SD)*	EASE	EASE <sub>Δ</sub>	CIs excl. null (%)
None	471,321 (100.0%)	11,716 (100.0%)	0.00 (0.48)	0.38	-	15.2%
All <sup>†</sup>	54,358 (11.5%)	1,633 (13.9%)	0.00 (0.00)	0.00	-0.38	3.9%
MDRR < 10	447,445 (94.9%)	11,233 (95.9%)	0.00 (0.48)	0.38	0.00	15.7%
Equipoise > 0.5	136,405 (28.9%)	2,792 (23.8%)	0.00 (0.02)	0.02	-0.36	4.7%
Equipoise > 0.1	413,489 (87.7%)	10,010 (85.4%)	0.00 (0.41)	0.33	-0.05	13.5%
Covariate balance SDM < 0.1	204,758 (43.4%)	4,923 (42.0%)	0.00 (0.35)	0.28	-0.10	11.0%
Generalizability SDM < 0.25	203,986 (43.3%)	4,942 (42.2%)	0.03 (0.47)	0.37	-0.01	13.9%
EASE < 0.25	394,953 (83.8%)	9,718 (82.9%)	0.00 (0.44)	0.35	-0.03 <sup>‡</sup>	14.3%